Pertussis, commonly known as whooping cough, is a highly contagious respiratory disease caused by the bacterium Bordetella pertussis. It poses significant health risks, particularly to infants and young children, and can lead to severe complications such as pneumonia, seizures, and, in extreme cases, death.
BioNet stands at the forefront of combating this disease through the development of genetically detoxified acellular pertussis vaccines. Utilizing advanced genetic engineering techniques, BioNet has created vaccines that are both safe and effective, providing robust immunity against pertussis. Their innovative approach has led to the advancement of proprietary recombinant pertussis vaccines from early research and development to licensure.
Genetically-Inactivated Pertussis Toxin
We are leading the development and manufacturing of next generation Recombinant Pertussis Vaccines (RPV):
› Recombinant aP; booster, stand-alone pertussis (licensed)
› Recombinant TdaP; booster, combination vaccine (licensed)
› Recombinant Tdap; booster, reduced-dose pertussis, combination vaccine (licensed)
› Recombinant ap ; booster, reduced-dose pertussis, stand-alone
› Recombinant DTaP; pediatric, combination vaccine
The safety and superior immunogenicity of our recombinant pertussis vaccines has been demonstrated in more than 15 clinical trials worldwide (see clinical trials/publications).
Among BioNet’s leading products are Pertagen® and Boostagen®.
Through these innovative vaccines, BioNet continues to lead the fight against pertussis, contributing significantly to global public health efforts aimed at reducing the incidence and impact of this preventable disease.
Clinical Trials
Find out more about our current clinical trials and their impact on vaccine innovation.
Adolescent
5-year Follow-up After a Single Dose Acellular Pertussis Vaccination
Read more >
A phase II/III randomized, observer-blind, controlled study to demonstrate non-inferior immunogenicity of a combined tetanus-diphtheria-acellular Pertussis vaccine as compared to Adacel® vaccine in healthy subjects aged 12-17 years
Read more >
A phase II randomized, observer-blind controlled pilot study to compare the safety and immunogenicity of acellular pertussis vaccines including chemically or genetically-detoxified pertussis toxin in adolescents aged 11-15 years previously immunized with acellular pertussis vaccines
Read more >
Young adults
An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-30 years
Read more >
A phase I/II randomized, observer-blind, controlled study to assess safety and immunogenicity of acellular pertussis vaccine given alone or in combination with tetanus-diphtheria vaccine in healthy adults aged 18-35 years
Read more >
Adults and elderly
Safety and antibody responses in adults and elderly after immunization with a recombinant pertussis booster dose
Read more >
Pregnant women
Antibody level in cord sera following immunization with recombinant acellular pertussis vaccines during pregnancy: a prospective, observational study
Read more >
A phase II randomized, observer-blind, active-controlled study to evaluate the immunogenicity and the safety of BioNet recombinant pertussis vaccines with different doses of genetically detoxified pertussis toxin (PTgen) when administered to healthy pregnant women
Read more >
Immunogenicity and safety of various recombinant acellular pertussis-containing vaccines in healthy pregnant women
Read more >
Special population: pregnant women living with HIV
The safety and immunogenicity of combined pertussis-containing vaccine (Tdap) for HIV-infected pregnant women and their newborns – a randomized clinical trial
Read more >
Disclaimer: The trademarks Pertagen® and Boostagen® are owned by BioNet and are used in accordance with applicable trademark laws. Availability of these products may vary by country and is subject to local regulatory approval. The information provided on this webpage is intended for informational purposes only and should not be considered as medical advice or a substitute for professional healthcare consultation.